TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06828848: An Open-label, Multicentre, Single-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VaboremⓇ (Meropenem-Vaborbactam) in Paediatric Population With Suspected or Confirmed Gram Negative Infections, I

Sponsor: Menarini Group · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 44 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$352,800

Rescue Site Savings

+$235,200

Unlock Full NCT06828848 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06828848 Rescue Dossier →